# A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA

> **NCT01078597** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 35 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01078597
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078597, "A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01078597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*